Xarelto (rivaroxaban) is a prescription medication used for the prevention of blood clots by patients who have had knee or hip surgery or who have atrial fibrillation. The first lawsuit for damages and injuries allegedly caused by Xarelto were filed in 2013 against Bayer after a Kentucky woman was hospitalized after taking Xarelto and suffering severe gastrointestinal bleeding.
Xarelto (rivaroxaban) is an anti-coagulant, designed primarily for patients who are at risk for deep vein thrombosis (DVT) after a hip or knee replacement. Produced by the German-based pharmaceutical firm Bayer A.G., Xarelto is currently marketed by Janssen Pharmaceutica, a Belgian company and a division of Johnson & Johnson.
Lawsuits have been filed against the manufacturer of Xarelto by patients who have suffered severe and uncontrollable bleeding and death after taking Xarelto. Claimants claim Bayer failed to notify users of the potential serious and deadly side-effects of the medication, specifically that uncontrollable bleeding could occur, and if it did, there was no treatment, increasing the risk of fatal hemorrhaging. Other side-effects from the medication which can cause severe injuries and can be very costly for patients includes diarrhea, arrhythmia, tachycardia, sudden changes in blood pressure, burning or itching skin, numbness and back pain, gastrointestinal or bladder problems, difficulty in swallowing, headaches, dizziness, weakness or pain in the extremities.
Bayer Healthcare business operations includes animal health, pharmaceuticals, consumer care, and medical care. Bayer Healthcare employs more than 60,000 employees worldwide and generates 19,975 Euro million in annual sales. Bayer Healthcare is currently headquartered in Leverkusen, Germany.
Xarelto (rivaroxaban) is manufactured by Bayer, but it is marketed by Johnson & Johnson’s Janssen Pharmaceuticals unit. Janssen Pharmaceuticals, Inc., is located in Titusville, New Jersey. The company was started by Dr. Paul Janssen, a leading Belgian researcher, pharmacologist, and general practitioner who pioneered mental health medication. Janssen joined with Johnson & Johnson in 1961. Johnson & Johnson is a multinational, pharmaceutical company which manufactures, markets, and sells a broad array of medications for various conditions and products for everyday use.
Companies who decide to manufacture, market, and sell medications have the legal responsibility to educate users about the possible destructive symptoms of their medications. Users of Xarelto suggest Bayer may have failed in their responsibility to notify users of all of the side-effects of Xarelto. Although the medication was approved by the FDA in 2011, claimants allege Bayer has not done enough to notify the Xarelto users of the most dangerous side-effect of Xarelto, which is uncontrollable bleeding.
If you have had a financial hardship such as emergency room visit, lost wages, and high medical costs associated with Xarelto or if you have suffered pain or other injuries from its use, you may be entitled to compensation. Many claimants have decided to file lawsuits against Bayer and Janssen Pharmaceuticals to hold them accountable for releasing a dangerous drug and failing to inform the public. The manufacturer has countered the claims of the plaintiffs arguing that all blood thinners increase the risk of bleeding, a fact that is not only well-known but clearly reported on the packaging.